SLBT SL Science Holding Limited
$2.06▼ -1.90%
Healthcare
Other
After hours
$2.14▲ +3.88%
Sep 11, 7:53 PM ET
Volume 43.6K
Avg Volume (10D) 84.8K
Key Metrics & Fundamentals
Market Cap
$1.16B
P/E Ratio
–
Div Yield
–%
52W Range
2.01 - 14.50
% vs 50 MA
-35.75%
% vs 200 MA
-73.11%
RSI-14
33.4
MACD Histogram
-0.0200
Beta (1Y vs SPY)
0.15
Gross Rev
–
Gross Profit
–
EBITDA
–
COGS
–
Operating Exp
–
Operating Income
–
EBIT
–
Pretax Income
–
Net Income
–
Price & Volume History
Loading chart…
Recent News
SL Science Holding Limited Rings Nasdaq Bell, Capping an Active First Quarter as a Publicly Traded Company
GlobeNewswire · Sep 2, 2026 8:10 PM
SL Science Highlights New FDA Drug Master File for GDT Cell-Derived Exosomes, Expanding the Regulatory Foundation of its Platform
GlobeNewswire · Aug 27, 2026 12:00 PM
SL Science Holding (SLBT) Stock May Be Fully Priced Even After A 74% Fall
Simply Wall St. · Aug 18, 2026 5:13 PM
SL Science Leadership Co-Authors Peer-Reviewed Framework for Clinical Development of γδ T Cell Therapy in Glioblastoma
GlobeNewswire · Aug 11, 2026 12:00 PM
SL Science Announces Successful Exhibition of Breakthrough Brain Cancer Therapy Research at the 2026 World Congress of Basic and Clinical Pharmacology
GlobeNewswire · Jul 17, 2026 12:00 PM
Sector Update: Healthcare Stocks Decline Late Afternoon
MT Newswires · Jul 10, 2026 7:50 PM
Sector Update: Healthcare
MT Newswires · Jul 10, 2026 7:39 PM
Sector Update: Healthcare Stocks Advance Premarket Friday
MT Newswires · Jul 10, 2026 1:15 PM
SL Science Submits Orphan Drug Designation Request to FDA for GDT Cell Therapy in Glioblastoma
MT Newswires · Jul 10, 2026 12:20 PM
SL Science Holding Limited Submits Orphan Drug Designation Request to the U.S. FDA for GDT Cell Therapy Targeting Glioblastoma
GlobeNewswire · Jul 10, 2026 12:00 PM
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
Social Sentiment
No Reddit posts found for SLBT.
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.